The glycoprotein of vesicular stomatitis virus promotes release of virus-like particles from tetherin-positive cells
- PMID: 29216247
- PMCID: PMC5720808
- DOI: 10.1371/journal.pone.0189073
The glycoprotein of vesicular stomatitis virus promotes release of virus-like particles from tetherin-positive cells
Abstract
Vesicular stomatitis virus (VSV) release from infected cells is inhibited by the interferon (IFN)-inducible antiviral host cell factor tetherin (BST-2, CD317). However, several viruses encode tetherin antagonists and it is at present unknown whether residual VSV spread in tetherin-positive cells is also promoted by a virus-encoded tetherin antagonist. Here, we show that the viral glycoprotein (VSV-G) antagonizes tetherin in transfected cells, although with reduced efficiency as compared to the HIV-1 Vpu protein. Tetherin antagonism did not involve alteration of tetherin expression and was partially dependent on a GXXXG motif in the transmembrane domain of VSV-G. However, mutation of the GXXXG motif did not modulate tetherin sensitivity of infectious VSV. These results identify VSV-G as a tetherin antagonist in transfected cells but fail to provide evidence for a contribution of tetherin antagonism to viral spread.
Conflict of interest statement
Figures
References
-
- Letchworth GJ, Rodriguez LL, Del cJ. (1999) Vesicular stomatitis. Vet J 157: 239–260. doi: 10.1053/tvjl.1998.0303 - DOI - PubMed
-
- Mead DG, Ramberg FB, Besselsen DG, Mare CJ. (2000) Transmission of vesicular stomatitis virus from infected to noninfected black flies co-feeding on nonviremic deer mice. Science 287: 485–487. - PubMed
-
- Rodriguez LL. (2002) Emergence and re-emergence of vesicular stomatitis in the United States. Virus Res 85: 211–219. - PubMed
-
- Lichty BD, Power AT, Stojdl DF, Bell JC. (2004) Vesicular stomatitis virus: re-inventing the bullet. Trends Mol Med 10: 210–216. doi: 10.1016/j.molmed.2004.03.003 - DOI - PubMed
-
- Balachandran S, Porosnicu M, Barber GN. (2001) Oncolytic activity of vesicular stomatitis virus is effective against tumors exhibiting aberrant p53, Ras, or myc function and involves the induction of apoptosis. J Virol 75: 3474–3479. doi: 10.1128/JVI.75.7.3474-3479.2001 - DOI - PMC - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
